Laurus Labs announced strong H1 FY26 results, with revenue reaching ₹3,223 Cr, a 33% increase. EBITDA stood at ₹818 Cr, with a margin of 25.4%. The company is investing in manufacturing network expansion and capabilities, allocating 15% of sales to CAPEX. Strategic investments include land acquisition and expansions in pharma manufacturing and R&D.
Financial Highlights
Laurus Labs reported a robust H1 FY26 performance:
- Revenue: ₹3,223 Cr, up 33%.
- EBITDA: ₹818 Cr, margin at 25.4%, increased by 10.8% pts.
- Gross Margins: Expanded by over 4.5% pts to 59.6%.
Strategic Investments
The company is making significant investments to secure future growth:
- Acquired 532 acres of land in Vizag for a new pharma complex.
- Plans to invest over US $600mn in pharma manufacturing and R&D.
- Invested US $2mn in Aarvik Therapeutics to access antibody-drug conjugate technology.
Business Segment Performance
Here’s a breakdown of revenue by segment for H1 FY26:
- CDMO: ₹1,040 Cr, a 74% increase.
- Generics: ₹2,183 Cr, a 20% increase.
Q2 FY26 Performance
Key figures for Q2 FY26 include:
- Revenue: ₹1,653 Cr, up 35%.
- EBITDA: ₹429 Cr, up 136%.
- Net Profit: ₹195 Cr, up 875%.
Future Outlook
Laurus Labs expects continued momentum in FY26, driven by a robust CDMO industry outlook and generics growth. The company will maintain balance sheet discipline while supporting long-term growth through strategic CAPEX investments.
Source: BSE